Artículos del autor

Dr. Carlos Fava

Member of the Editorial Board of solaci.org

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe...

Paclitaxel-Eluting vs. Sirolimus-Eluting Balloons

Coronary restenosis remains one of the main challenges in percutaneous transluminal coronary angioplasty (PTCA), especially nowadays, when...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series....

Asymmetry in the Implantation of Self-Expanding Valves in TAVR: Evolution at 5 Years

Severe aortic stenosis is frequently associated with significant and irregular calcification, which tends to be more present...

SCAAR Registry: Coronary Angioplasty in Venous Grafts

Most patients undergoing coronary artery bypass graft (CABG) benefit from at least one saphenous vein graft (SVG)....

ENVISAGE-TAVI AF Trial: What Anticoagulant Should We Use?

Between 15% and 30% of patients undergoing TAVR present atrial fibrillation. Many of them have suffered ischemic...